A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

India’s COVID-19 cases are surging again, with over 6,100 active infections and six new deaths, driven by Omicron subvariants ...

It’s the silent, progressive disease that slowly is killing millions of Australians – but most don’t know they have it.

NEW YORK, June 7, 2025 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM). Such investors are advised to contact ...

The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...